Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction

The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) and dual SGLT1/2 inhibitor sotagliflozin (SOTA) are emerging as heart failure (HF) medications in addition to having glucose-lowering effects in diabetes mellitus (DM). However, the precise mechanism underlying this cardioprot...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Inho, Cho, Hyun-Jai, Lim, Soo, Seok, Seung Hyeok, Lee, Hae-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318005/
https://www.ncbi.nlm.nih.gov/pubmed/37258583
http://dx.doi.org/10.1038/s12276-023-01002-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318005/
https://www.ncbi.nlm.nih.gov/pubmed/37258583
http://dx.doi.org/10.1038/s12276-023-01002-3

Ejemplares similares